Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $0.40, $0.46 worse than the analyst estimate of $0.86. Revenue for the quarter came in at $530.6 million versus the consensus estimate of $525.4 million.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.